View source for PL-6983

{{Short description|Chemical compound}}
{{Infobox drug
| drug_name = 
| image = 
| width = 
| caption = 

<!-- Clinical data -->
| pronounce = 
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_CA = 
| licence_EU = 
| DailyMedID = 
| licence_US = 
| pregnancy_AU = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Subcutaneous injection]]
| class = [[Melanocortin]] [[melanocortin 4 receptor|MC<sub>4</sub> receptor]] [[agonist]]
| ATC_prefix = 
| ATC_suffix = 

<!-- Legal status -->
| legal_status = 

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 
| duration_of_action = 
| excretion = 

<!-- Identifiers -->
| CAS_number = 1966957-74-3
| CAS_supplemental = 
| PubChem = 
| PubChemSubstance = 472219121
| IUPHAR_ligand = 
| DrugBank = 
| ChemSpiderID = 
| UNII = 
| KEGG = 
| ChEBI = 
| ChEMBL = 
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = 

<!-- Chemical data -->
| IUPAC_name = 
| C= | H= | N= | O= 
| SMILES = 
| StdInChI = 
| StdInChIKey = 
}}

'''PL-6983''' is a [[synthetic compound|synthetic]] [[peptide]] and [[binding selectivity|selective]] [[Melanocortin 4 receptor|MC<sub>4</sub> receptor]] [[agonist]] which is under development by Palatin Technologies for the treatment of [[female sexual dysfunction]] and [[erectile dysfunction]].<ref name="Simon_2009">{{cite journal | vauthors = Simon JA | title = Opportunities for intervention in HSDD | journal = The Journal of Family Practice | volume = 58 | issue = 7 Suppl Hypoactive | pages = S26–30 | date = July 2009 | pmid = 19825316 | doi = |url= http://www.oncologypractice.com/fileadmin/jfp_archive/pdf/5807JFP_DIMEsupplv2.pdf |access-date=2015-05-14 |archive-url= https://web.archive.org/web/20150518075528/http://www.oncologypractice.com/fileadmin/jfp_archive/pdf/5807JFP_DIMEsupplv2.pdf |archive-date=2015-05-18 |url-status=dead | veditors = Mitchner N }}</ref><ref name="KrychmanFinestone2010">{{cite book| vauthors = Krychman ML, Finestone S |title=100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy|url=https://books.google.com/books?id=poiGbNuPj9sC&pg=PA120|date=25 October 2010|publisher=Jones & Bartlett Publishers|isbn=978-1-4496-1936-7|pages=120–}}</ref> It was developed as a successor to/replacement of [[bremelanotide]] (PT-141) due to concerns of the [[side effect]] of increased [[blood pressure]] seen with the latter in [[clinical trial]]s.<ref name="Simon_2009" /><ref name="KrychmanFinestone2010" /> Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in [[animal model]]s.<ref name="Simon_2009" /><ref name="KrychmanFinestone2010" /> The drug has reportedly been in [[pre-clinical development]] for all medical indications since 2008.<ref>{{Cite web|url=https://adisinsight.springer.com/drugs/800028349|title=Research programme: sexual dysfunction therapy - Palatin Technologies | work = AdisInsight | publisher = Springer Nature Switzerland AG |access-date=2019-06-06}}</ref> Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."<ref>{{Cite web|url=http://www.palatin.com/products/6983.asp|title=Palatin Technologies - PL-6983 for Female Sexual Dysfunction|date=2015-05-26|archive-url=https://web.archive.org/web/20150526024025/http://www.palatin.com/products/6983.asp|archive-date=2015-05-26}}</ref> The [[chemical structure]] of PL-6983 has yet to be made public.

== See also ==
* [[List of investigational sexual dysfunction drugs]]
* [[Melanocortin 4 receptor#Agonists|Melanocortin 4 receptor § Agonists]]

== References ==
{{Reflist}}

== External links ==
*[https://web.archive.org/web/20150526024025/http://www.palatin.com/products/6983.asp PL-6983 for Sexual Dysfunction - Palatin Technologies]
*[https://web.archive.org/web/20150924063440/http://www.palatin.com/pdfs/pl-6983.pdf PL-6983 for Female Sexual Dysfunction - Palatin Technologies]
*[http://www.genengnews.com/gen-news-highlights/palatin-obtains-21-1m-to-advance-programs-in-female-sexual-dysfunction-and-asthma/81244763/ Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News]
*[http://adisinsight.springer.com/drugs/800028349 Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight]
*[https://nutri-medi.com/sildenax-funciona/ How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi]
*{{usurped|1=[https://web.archive.org/web/20200803153216/https://vera-farmacia.com/ How Medicines Work To Improve Potency - Vera Farmacia]}}

{{Sexual dysfunction pharmacotherapies}}
{{Melanocortin receptor modulators}}

[[Category:Aphrodisiacs]]
[[Category:Drugs with undisclosed chemical structures]]
[[Category:Erectile dysfunction drugs]]
[[Category:Female sexual dysfunction drugs]]
[[Category:Melanocortin receptor agonists]]
[[Category:Peptide therapeutics]]
{{Nervous-system-drug-stub}}